For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab ...
AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...
Experts at HLTH Europe 2026 agreed that healthcare innovations won't meet their full potential until healthcare services can implement them.
Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...
Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an increasingly intertwined human-machine model moves closer to adoption in real-world ...
From horrible side effects that could send a patient to the hospital, drugs to fight a deadly skin cancer have come a long ...
The tracking mechanism will be implemented over the next two years — by July 2027 for vaccines, narcotics, and anticancer ...
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...
10d
Every cancer drug vial, vaccine, antibiotic to get unique QR code under new anti-counterfeit rules
Move to enable end-to-end tracking from factory to patient; phased rollout begins in 2027 after concerns over fake cancer ...
Tigerlily Foundation welcomes the U.S. Food and Drug Administration's approval of Trodelvy® (sacituzumab govitecan-hziy) as a first-line treatment option for patients with metastatic triple-negative ...
In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results